• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New potent inhibitors of angiotensin converting enzyme.

作者信息

Attwood M R, Francis R J, Hassall C H, Kröhn A, Lawton G, Natoff I L, Nixon J S, Redshaw S, Thomas W A

出版信息

FEBS Lett. 1984 Jan 9;165(2):201-6. doi: 10.1016/0014-5793(84)80169-6.

DOI:10.1016/0014-5793(84)80169-6
PMID:6319181
Abstract

Using an earlier model of the favoured orientation of binding functions of angiotensin converting enzyme (ACE) inhibitors, it has been possible to postulate a new, 7,6-bicyclic system, based on hexahydropyridazine, which might be expected to have high potency. Some members of this system which have been synthesised have been shown to be very active ACE inhibitors, in vitro and in vivo.

摘要

相似文献

1
New potent inhibitors of angiotensin converting enzyme.
FEBS Lett. 1984 Jan 9;165(2):201-6. doi: 10.1016/0014-5793(84)80169-6.
2
Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
J Cardiovasc Pharmacol. 1985 May-Jun;7(3):569-80. doi: 10.1097/00005344-198505000-00025.
3
The present molecules of converting enzyme inhibitors.目前的血管紧张素转换酶抑制剂分子。
J Cardiovasc Pharmacol. 1985;7 Suppl 1:S2-11. doi: 10.1097/00005344-198507001-00002.
4
Influence of the converting enzyme inhibitors Hoe 498, enalapril and captopril on vascular reactivity of isolated arterial preparations.
Clin Exp Hypertens A. 1984;6(10-11):1807-13. doi: 10.3109/10641968409046083.
5
The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.人在接受血管紧张素I激发后血管紧张素转换酶（ACE）活性的评估：西拉普利、卡托普利和依那普利的比较
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):217S-223S. doi: 10.1111/j.1365-2125.1989.tb03485.x.
6
Effects of chronic converting enzyme inhibition on the vascular renin-angiotensin system.慢性转换酶抑制对血管肾素-血管紧张素系统的影响。
Clin Exp Pharmacol Physiol. 1990 Nov;17(11):745-53. doi: 10.1111/j.1440-1681.1990.tb01276.x.
7
Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.2-[N-[(S)-1-羧基-3-苯基丙基]-L-丙氨酰]-(1S,3S,5S)-2-氮杂双环[3.3.0]辛烷-3-羧酸（Hoe 498二酸）对血管紧张素转换酶的抑制作用。与卡托普利和依那普利拉的比较。
Arzneimittelforschung. 1984;34(10B):1406-10.
8
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).七种结构各异的血管紧张素转换酶（ACE）抑制剂作用的体外、离体和体内比较。
Br J Clin Pharmacol. 1989;28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. doi: 10.1111/j.1365-2125.1989.tb03587.x.
9
Kinetics of captopril- and enalapril-induced inhibition of pulmonary angiotensin converting enzyme in vivo.
J Pharmacol Exp Ther. 1985 Aug;234(2):372-7.
10
Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid.卡托普利和依那普利二酸对血管紧张素转换酶的抑制动力学。
Biochem Pharmacol. 1984 Apr 15;33(8):1273-6. doi: 10.1016/0006-2952(84)90180-1.

引用本文的文献

1
Sequential allylic C-H amination/vinylic C-H arylation: a strategy for unnatural amino acid synthesis from α-olefins.连续烯丙基 C-H 胺化/乙烯基 C-H 芳基化：一种从α-烯烃合成非天然氨基酸的策略。
Org Lett. 2012 Mar 16;14(6):1386-9. doi: 10.1021/ol300063t. Epub 2012 Feb 24.
2
Preclinical studies on angiotensin converting enzyme inhibitors.血管紧张素转换酶抑制剂的临床前研究。
Cardiovasc Drugs Ther. 1987;1(1):15-27. doi: 10.1007/BF02125829.
3
Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
依那普利。对其药效学和药代动力学特性以及在高血压和充血性心力衰竭中的治疗用途的综述。
Drugs. 1986 Mar;31(3):198-248. doi: 10.2165/00003495-198631030-00002.
4
Prodrugs.前体药物
Br J Clin Pharmacol. 1989 Nov;28(5):497-507. doi: 10.1111/j.1365-2125.1989.tb03535.x.
5
Chemical design of cilazapril.西拉普利的化学设计。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):133S-137S. doi: 10.1111/j.1365-2125.1989.tb03474.x.
6
Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function.单次及连续服用西拉普利对肾功能正常或受损的高血压患者的降压效果及药代动力学研究
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):283S-287S. doi: 10.1111/j.1365-2125.1989.tb03493.x.
7
Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.慢性心力衰竭对大鼠血管紧张素I反应性及西拉普利抑制血管紧张素转换酶作用的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):167S-174S. doi: 10.1111/j.1365-2125.1989.tb03478.x.
8
Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.急性和慢性西拉普利治疗对自发性高血压大鼠的影响。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):151S-158S. doi: 10.1111/j.1365-2125.1989.tb03476.x.
9
A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.新型血管紧张素转换酶抑制剂西拉普利的临床前心血管药理学综述。
Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S. doi: 10.1111/j.1365-2125.1989.tb03475.x.
10
Vascular protection with cilazapril.
Drugs. 1991;41 Suppl 1:62-7. doi: 10.2165/00003495-199100411-00011.